(91 days)
No
The document describes a bone conduction hearing implant system that uses mechanical vibrations to stimulate the auditory system. There is no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is intended to augment hearing by providing acoustic input to the inner ear via bone conduction for patients with hearing loss, which is a therapeutic intervention.
No
The device description clearly states that BONEBRIDGE is a hearing implant system that augments hearing by providing acoustic input to the inner ear via bone conduction. It is a treatment device, not a diagnostic one.
No
The device description clearly outlines both an implantable hardware component (Bone Conduction Implant - BCI) and an externally worn audio processor, indicating it is a hardware-based medical device system, not software-only.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, or tissue) to provide information about a person's health.
- Device Function: The BONEBRIDGE system is a hearing implant that works by directly stimulating the auditory system through bone conduction. It does not analyze biological samples.
- Intended Use: The intended use is to augment hearing for individuals with specific types of hearing loss, not to diagnose a condition based on laboratory analysis.
- Device Description: The description details an implantable device and an external processor that work together to transmit sound vibrations, not to perform diagnostic tests on samples.
Therefore, the BONEBRIDGE system falls under the category of a therapeutic or assistive medical device, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The BONEBRIDGE bone conduction hearing implant system is intended for the following patients and indications:
- Patients 12 years of age or older.
- Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5,1, 2, and 3 kHz) should be better than or equal to 45 dB HL.
- Bilateral fitting of the BONEBRIDGE is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than15 dB at individual frequencies.
- Patients who have profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at0.5, 1, 2, and 3 kHz).
- The BONEBRIDGE for SSD is also indicated for any patient who is indicated for an airconduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
- Prior to receiving the device, it is recommended that an individual have experience with appropriately fit air conduction or bone conduction hearing aids.
Product codes
PFO
Device Description
BONEBRIDGE augments hearing by providing acoustic input to the inner ear via bone conduction. BONEBRIDGE consists of the following components: The Bone Conduction Implant (BCI) and the externally worn audio processor.
The BCI 601 implant is provided in an implant kit together with two templates to determine optimal implant placement, one drill bit, two regular cortical titanium screws (gold surface) and one emergency screw (blue surface).
All devices are shipped in one sterile tray and are for single-use only.
Contents of the BCI 601 Implant Kit
- Coil-Sizer (template representing coil section, see Figure 2, called "C-Sizer")
- Transducer-Sizer (template representing transducer section, see Figure 2, called "T-Sizer")
- Cortical titanium screws [2 regular screws (gold surface), 1 emergency screw (blue surface)]
- Drill bit with stopper (requires handpiece with dental coupling)
- Bone Conduction Implant (BCI 601)
The Bone Conduction Implant (BCI) is the implantable part of BONEBRIDGE and can only be used together with compatible MED-EL external components. The device is an osseointegrated bone conduction implant system, intended to provide a level of useful sound perception for individuals with conductive and mixed hearing loss, as well as those suffering from single-sided deafness. The BCI is surgically implanted into the mastoid bone.
The BCI 601 has two main sections, the coil section and the transducer section.
The BCl 601 consists of a magnet surrounded by the receiver coil, the electronics (demodulator), the transition and the Bone Conduction - Floating Mass Transducer (BC-FMT). The BCI 601 is activated by placing the external audio processor over the magnet of the BCI 601. The signal and the energy to drive the BC-FMT are transferred via an inductive link to the internal coil, processed by the demodulator and then relayed to the BC-FMT. The BC-FMT transduces the signal into mechanical vibrations, which are conducted to the mastoid bone via the cortical titanium screws. These vibrations stimulate the auditory system through the bone conduction pathway to allow the patient to hear.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Mastoid bone
Indicated Patient Age Range
12 years of age or older.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
All necessary bench testing was conducted on BONEBRIDGE to support a determination of substantial equivalence to the existing BONEBRIDGE. The non-clinical bench tests supporting the labelling update included:
- Electromagnetic compatibility testing and
- MRI compatibility testing.
The collective results of the non-clinical testing demonstrate that BONEBRIDGE meets the established specifications to ensure consistent and safe performance for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 874.3340 Active implantable bone conduction hearing system.
(a)
Identification. An active implantable bone conduction hearing system is a prescription device consisting of an implanted transducer, implanted electronics components, and an audio processor. The active implantable bone conduction hearing system is intended to compensate for conductive or mixed hearing losses by conveying amplified acoustic signals to the cochlea via mechanical vibrations on the skull bone.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Clinical performance testing must characterize any adverse events observed during implantation and clinical use, and must also demonstrate that the device performs as intended under anticipated conditions of use.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including the following:
(i) Performance data must validate force output in a clinically relevant model.
(ii) Impact testing in a clinically relevant anatomic model must be performed.
(iii) Mechanical integrity testing must be performed.
(iv) Reliability testing consistent with expected device life must be performed.
(3) The patient-contacting components of the device must be demonstrated to be biocompatible.
(4) Performance data must demonstrate the sterility of the patient-contacting components of the device.
(5) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
(6) Performance data must demonstrate the wireless compatibility, electromagnetic compatibility, and electrical safety of the device.
(7) Software verification, validation, and hazard analysis must be performed.
(8) Labeling must include:
(i) A summary of clinical testing conducted with the device that includes a summary of device-related complications and adverse events;
(ii) Instructions for use;
(iii) A surgical guide for implantation, which includes instructions for imaging to assess bone dimensions;
(iv) A shelf life, for device components provided sterile;
(v) A patient identification card; and
(vi) A patient user manual.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square are the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" below in a smaller font.
March 7, 2019
MED-EL Elektromedizinische Geraete GmbH Stephanie Haselwanter Team Leader, Global Registrations Fuerstenweg 77a Innsbruck, 6020 At
Re: K183373
Trade/Device Name: Bonebridge Regulation Number: 21 CFR 874.3340 Regulation Name: Active implantable bone conduction hearing system Regulatory Class: Class II Product Code: PFO Dated: November 29, 2018 Received: December 6, 2018
Dear Stephanie Haselwanter:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device. please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely yours.
Srinivas Nandkumar -S
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K183373
Device Name
BONEBRIDGE
Indications for Use (Describe)
The BONEBRIDGE bone conduction hearing implant system is intended for the following patients and indications:
- · Patients 12 years of age or older.
· Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5,1, 2, and 3 kHz) should be better than or equal to 45 dB HL.
· Bilateral fitting of the BONEBRIDGE is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5. 1, 2. and 3 kHz, or less than15 dB at individual frequencies.
· Patients who have profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., singlesided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at0.5, 1, 2, and 3 kHz).
· The BONEBRIDGE for SSD is also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
· Prior to receiving the device, it is recommended that an individual have experience with appropriately fit air conduction or bone conduction hearing aids.
| Type of Use ( Select one or both, as applicable ) |
|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2020
See PRA Statement below.
3
This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR§807.92
510(k) Summary
- l. Submitter
Applicant:
MED-EL Elektromedizinische Geräte GmbH Fuerstenweg 77a 6020 Inssbruck AUSTRIA Phone +43 577 88 5622 Fax: +43 577 88 5690
Contact Person:
Stephanie Haselwanter Team Leader, Global Registrations, Regulatory Affairs MED-EL Elektromedizinische Geräte GmbH Fuerstenweg 77a 6020 Inssbruck AUSTRIA Phone +43 577 88 5622 Fax: +43 577 88 5690
-
II. Date Prepared
November 29th, 2018 -
III. Device
Trade Name: BONEBRIDGE
Generic/Common Name: Active Implantable Bone Conduction Hearing System
Classification: Class II, 21 CFR§874.3340
Classification Panel: Ear, Nose, and Throat
Product Code: PFO
IV. Predicate Devices
BONEBRIDGE (DEN170009)
- V. Purpose of Submission
4
The purpose of this premarket notification is to update the BONEBRIDGE product labelling for EMC and MRI to remove specific EMC cautionary information and to label the BCI 601 implant as MR conditional at 1.5T. The intended use of the modified device, as described in the labelling, has not changed as a result of the modification(s).
No changes have been made to the devices themselves. Only the product labelling is affected.
VI. Device Description
BONEBRIDGE augments hearing by providing acoustic input to the inner ear via bone conduction. BONEBRIDGE consists of the following components: The Bone Conduction Implant (BCI) and the externally worn audio processor.
The BCI 601 implant is provided in an implant kit together with two templates to determine optimal implant placement, one drill bit, two regular cortical titanium screws (gold surface) and one emergency screw (blue surface).
All devices are shipped in one sterile tray and are for single-use only.
Contents of the BCI 601 Implant Kit
- Coil-Sizer (template representing coil section, see Figure 2, called "C-Sizer")
- � Transducer-Sizer (template representing transducer section, see Figure 2, called "T-Sizer")
- € Cortical titanium screws [2 regular screws (gold surface), 1 emergency screw (blue surface)]
- � Drill bit with stopper (requires handpiece with dental coupling)
- Bone Conduction Implant (BCI 601)
Image /page/4/Figure/12 description: The image shows a top-down view of a container with several components inside. There are five distinct components labeled with numbers 1 through 5. Component 1 is a circular object with a symbol inside, while component 2 is a rectangular piece. Component 3 consists of three similar-looking objects, and component 4 is a long, thin object. Component 5 is another circular object with a different symbol inside.
The Bone Conduction Implant (BCI) is the implantable part of BONEBRIDGE and can only be used together with compatible MED-EL external components. The device is an osseointegrated bone conduction implant system, intended to provide a level of useful sound perception for individuals with conductive and mixed hearing loss, as well as those suffering from single-sided deafness. The BCI is surgically implanted into the mastoid bone.
5
Image /page/5/Figure/0 description: The image shows a diagram of a device with two sections, a coil section and a transducer section. The coil section has a magnet and coil, and the transducer section has anchor holes and is labeled BC-FMT. The dimensions of the device are labeled, including 28.6 mm (1.13 in.) for the coil section, 23.8 mm (0.94 in.) for the transducer section, 4.5 mm (0.18 in.) for the height of the coil, 8.7 mm (0.34 in.) for the height of the transducer, 15.8 mm (0.62 in.) for the diameter of the transducer, and 69 mm (2.72 in.) for the total length of the device.
The BCI 601 has two main sections, the coil section and the transducer section.
The BCl 601 consists of a magnet surrounded by the receiver coil, the electronics (demodulator), the transition and the Bone Conduction - Floating Mass Transducer (BC-FMT). The BCI 601 is activated by placing the external audio processor over the magnet of the BCI 601. The signal and the energy to drive the BC-FMT are transferred via an inductive link to the internal coil, processed by the demodulator and then relayed to the BC-FMT. The BC-FMT transduces the signal into mechanical vibrations, which are conducted to the mastoid bone via the cortical titanium screws. These vibrations stimulate the auditory system through the bone conduction pathway to allow the patient to hear.
VII. Intended Use & Indications for Use
The BONEBRIDGE bone conduction hearing implant system is intended for the following patients and indications:
- . Patients 12 years of age or older.
- . Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5,1, 2, and 3 kHz) should be better than or equal to 45 dB HL.
- Bilateral fitting of the BONEBRIDGE is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than15 dB at individual frequencies.
6
- . Patients who have profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at0.5, 1, 2, and 3 kHz).
- The BONEBRIDGE for SSD is also indicated for any patient who is indicated for an airconduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
- . Prior to receiving the device, it is recommended that an individual have experience with appropriately fit air conduction or bone conduction hearing aids.
VIII. Technological Characteristics
BONEBRIDGE is an active implantable bone conduction hearing system. BONEBRIDGE is a prescription device consisting of an implanted transducer, implanted electronics components, and an audio processor. The active implantable bone conduction hearing system is intended to compensate for conductive or mixed hearing losses by conveying amplified acoustic signals to the cochlea via mechanical vibrations on the skull bone. The updates to the BONEBRIDGE system do not affect the device intended use, fundamental operating principles or functional characteristics.
IX. Materials
The update to the EMC and MRI labelling of the BONEBRIDGE System does not affect the product materials which have been evaluated previously per 10993-1 and were shown to be biocompatible and safe for human use.
X. Performance Data
All necessary bench testing was conducted on BONEBRIDGE to support a determination of substantial equivalence to the existing BONEBRIDGE. The non-clinical bench tests supporting the labelling update included:
- . Electromagnetic compatibility testing and
- MRI compatibility testing. ●
The collective results of the non-clinical testing demonstrate that BONEBRIDGE meets the established specifications to ensure consistent and safe performance for its intended use.
XI. Conclusion
Based on the indications for use, technological characteristics, and substantial equivalence comparison to the predicate system, BONEBRIDGE has been shown to be safe and effective for its intended use.